<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Leap Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/leap-therapeutics-inc</link>
<description>Latest news and press releases for Leap Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/leap-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835935678dffbe2df10343d.webp</url>
<title>Leap Therapeutics Inc</title>
<link>https://6ix.com/company/leap-therapeutics-inc</link>
</image>
<item>
<title>Markel Insurance appoints James Shankland as Head of Ocean Cargo, U.S.</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/markel-insurance-appoints-james-shankland-as-head-of-ocean-cargo-us-66</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/markel-insurance-appoints-james-shankland-as-head-of-ocean-cargo-us-66</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>RICHMOND, Va., April 2, 2026 /PRNewswire/ -- Markel, the insurance operations within Markel Group Inc. (NYSE: MKL), announced today the appointment of James</description>
</item>
<item>
<title>Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/harmony-biosciences-strengthens-executive-team-with-new-appointment-and-announces-additions-to-its-board-67</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/harmony-biosciences-strengthens-executive-team-with-new-appointment-and-announces-additions-to-its-board-67</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Appointments support Harmony’s next phase of growth and long‑term value creation PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc.</description>
</item>
<item>
<title>Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/dermata-receives-notice-of-acceptance-of-australian-patent-application-for-topical-application-of-dermal-fillers-with-its-bioneedle-delivery-system-22</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/dermata-receives-notice-of-acceptance-of-australian-patent-application-for-topical-application-of-dermal-fillers-with-its-bioneedle-delivery-system-22</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -- The Company also has</description>
</item>
<item>
<title>Nanalysis Announces Fourth Quarter and Full Year 2025 Conference Call</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/nanalysis-announces-fourth-quarter-and-full-year-2025-conference-call-71</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/nanalysis-announces-fourth-quarter-and-full-year-2025-conference-call-71</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Hosting Call at 10am ET on Thursday, April 9thCALGARY, AB, April 2, 2026 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, FRA: 1N1), a</description>
</item>
<item>
<title>Xeriant Receives U.S. Patent Notice Allowance for its Breakthrough Fire-Resistant Composite Technology</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/xeriant-receives-us-patent-notice-allowance-for-its-breakthrough-fire-resistant-composite-technology-72</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/xeriant-receives-us-patent-notice-allowance-for-its-breakthrough-fire-resistant-composite-technology-72</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Positions the Company at the forefront of next-generation building materials BOCA RATON, Fla., April 02, 2026 (GLOBE NEWSWIRE) -- Xeriant, Inc. (OTCQB: XERI),</description>
</item>
<item>
<title>IFF Launches PureStrong™, a Probiotic Made Specifically for Dogs</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/iff-launches-purestrongtm-a-probiotic-made-specifically-for-dogs-32</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/iff-launches-purestrongtm-a-probiotic-made-specifically-for-dogs-32</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients and health & biosciences—is introducing PureStrong™, a</description>
</item>
<item>
<title>Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/cocrystal-pharma-receives-fda-fast-track-designation-for-cdi-988-for-norovirus-infection-treatment-and-preventive-77</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/cocrystal-pharma-receives-fda-fast-track-designation-for-cdi-988-for-norovirus-infection-treatment-and-preventive-77</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>FDA Fast Track designation supports accelerated development and expedites regulatory reviewNorovirus is responsible for an estimated 685 million global cases</description>
</item>
<item>
<title>Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/intelligent-bio-solutions-completes-clinical-cut-off-study-advances-fda-510k-clinical-program-targeting-multi-billion-dollar-us-drug-screening-market</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/intelligent-bio-solutions-completes-clinical-cut-off-study-advances-fda-510k-clinical-program-targeting-multi-billion-dollar-us-drug-screening-market</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k)</description>
</item>
<item>
<title>Guidefitter Deepens Strategic Partnership with Rocky Brands, Inc., Expands Platform to Include Muck and XTRATUF</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/guidefitter-deepens-strategic-partnership-with-rocky-brands-inc-expands-platform-to-include-muck-and-xtratuf-30</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/guidefitter-deepens-strategic-partnership-with-rocky-brands-inc-expands-platform-to-include-muck-and-xtratuf-30</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Expansion Builds on Longstanding Collaboration with Rocky Boots, Bringing Additional Rocky Brands Portfolio Leaders into Guidefitter's Professional</description>
</item>
<item>
<title>BrightSpire Capital, Inc. Announces First Quarter 2026 Earnings Release and Conference Call Dates</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/brightspire-capital-inc-announces-first-quarter-2026-earnings-release-and-conference-call-dates-31</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/brightspire-capital-inc-announces-first-quarter-2026-earnings-release-and-conference-call-dates-31</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- BrightSpire Capital, Inc. (NYSE: BRSP) (“BrightSpire Capital” or the “Company”) today announced it will release first quarter</description>
</item>
<item>
<title>LightInTheBox Files 2025 Annual Report on Form 20-F</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/lightinthebox-files-2025-annual-report-on-form-20-f-84</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/lightinthebox-files-2025-annual-report-on-form-20-f-84</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>SINGAPORE, April 2, 2026 /PRNewswire/ -- LightInTheBox Holding Co., Ltd. (NYSE: LITB) ("LightInTheBox" or the "Company"), a global consumer lifestyle company,</description>
</item>
<item>
<title>Letter to Shareholders from Marcus Lemonis, Executive Chairman and CEO: The Growth Phase</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/letter-to-shareholders-from-marcus-lemonis-executive-chairman-and-ceo-the-growth-phase-80</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/letter-to-shareholders-from-marcus-lemonis-executive-chairman-and-ceo-the-growth-phase-80</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>MURRAY, Utah--(BUSINESS WIRE)-- Bed Bath & Beyond, Inc. (NYSE: BBBY) (“Bed Bath & Beyond” or “BBBY”) has issued the following letter from Marcus Lemonis,</description>
</item>
<item>
<title>PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/puretech-announces-publication-of-phase-2b-elevate-ipf-trial-results-in-the-american-journal-of-respiratory-and-critical-care-medicine-38</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/puretech-announces-publication-of-phase-2b-elevate-ipf-trial-results-in-the-american-journal-of-respiratory-and-critical-care-medicine-38</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Deupirfenidone 825 mg TID monotherapy significantly slowed lung function decline versus placebo at 26 weeks in people with idiopathic pulmonary fibrosis</description>
</item>
<item>
<title>Wingstop Inc. to Announce Fiscal First Quarter 2026 Financial Results on April 29, 2026</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/wingstop-inc-to-announce-fiscal-first-quarter-2026-financial-results-on-april-29-2026-90</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/wingstop-inc-to-announce-fiscal-first-quarter-2026-financial-results-on-april-29-2026-90</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>DALLAS, April 2, 2026 /PRNewswire/ -- Wingstop Inc. (NASDAQ: WING) today announced that it will host a conference call and webcast to discuss its fiscal first</description>
</item>
<item>
<title>Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/biodexa-announces-partnership-with-syngene-to-manufacture-mtx240-gmp-clinical-trial-supplies-4</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/biodexa-announces-partnership-with-syngene-to-manufacture-mtx240-gmp-clinical-trial-supplies-4</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (Nasdaq: BDRX)</description>
</item>
<item>
<title>Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/lantern-pharma-invites-investors-analysts-and-shareholders-to-experience-the-future-of-drug-discovery-via-a-live-demo-of-withzetaai-the-worlds-first-multi-agentic-co-scientist-for-rare-cancers-830-am-eastern-april-9-2026-52</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/lantern-pharma-invites-investors-analysts-and-shareholders-to-experience-the-future-of-drug-discovery-via-a-live-demo-of-withzetaai-the-worlds-first-multi-agentic-co-scientist-for-rare-cancers-830-am-eastern-april-9-2026-52</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Briefing to Feature a Live Walkthrough, Demonstration of Key Features, The Market Opportunity & Industry Need, Competitive Positioning, and Platform</description>
</item>
<item>
<title>Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/abeona-therapeuticsr-announces-new-qualified-treatment-center-for-zevaskynr-in-new-york</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/abeona-therapeuticsr-announces-new-qualified-treatment-center-for-zevaskynr-in-new-york</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University</description>
</item>
<item>
<title>CSW Industrials Increases Quarterly Dividend by 11% to $0.30 Per Share and Repurchases $35M in Shares During the Fiscal Fourth Quarter of 2026</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/csw-industrials-increases-quarterly-dividend-by-11percent-to-dollar030-per-share-and-repurchases-dollar35m-in-shares-during-the-fiscal-fourth-quarter-of-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/csw-industrials-increases-quarterly-dividend-by-11percent-to-dollar030-per-share-and-repurchases-dollar35m-in-shares-during-the-fiscal-fourth-quarter-of-2026-5</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>DALLAS, April 02, 2026 (GLOBE NEWSWIRE) -- CSW Industrials, Inc. (NYSE: CSW) announced today that its Board of Directors has declared a regular quarterly cash</description>
</item>
<item>
<title>Zoetis to Host Webcast and Conference Call on First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/zoetis-to-host-webcast-and-conference-call-on-first-quarter-2026-financial-results-29</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/zoetis-to-host-webcast-and-conference-call-on-first-quarter-2026-financial-results-29</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026. Chief</description>
</item>
<item>
<title>SABINE ROYALTY TRUST ANNOUNCES MONTHLY CASH DISTRIBUTION FOR APRIL 2026</title>
<link>https://6ix.com/company/leap-therapeutics-inc/news/sabine-royalty-trust-announces-monthly-cash-distribution-for-april-2026-68</link>
<guid isPermaLink="true">https://6ix.com/company/leap-therapeutics-inc/news/sabine-royalty-trust-announces-monthly-cash-distribution-for-april-2026-68</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>DALLAS, April 2, 2026 /PRNewswire/ -- Argent Trust Company, as Trustee of the Sabine Royalty Trust (NYSE: SBR), today declared a cash distribution to the</description>
</item>
</channel>
</rss>